MY113294A - A process for the preparation of a virus inactivated fraction containing factor viii by means of chromatographic methods - Google Patents

A process for the preparation of a virus inactivated fraction containing factor viii by means of chromatographic methods

Info

Publication number
MY113294A
MY113294A MYPI94002921A MYPI19942921A MY113294A MY 113294 A MY113294 A MY 113294A MY PI94002921 A MYPI94002921 A MY PI94002921A MY PI19942921 A MYPI19942921 A MY PI19942921A MY 113294 A MY113294 A MY 113294A
Authority
MY
Malaysia
Prior art keywords
preparation
factor viii
fraction containing
chromatographic methods
containing factor
Prior art date
Application number
MYPI94002921A
Inventor
Djuro Josic Dr
Andrea Stadler Monika
Strancar Ales
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6501733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY113294(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of MY113294A publication Critical patent/MY113294A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A PROCESS FOR THE PREPARATION OF A VIRUS INACTIVATED FRACTION CONTAINING FACTOR VIII BY MEANS OF CHROMATOGRAPHIC METHODS, WHEREIN -PROCEEDING FROM A CRYOPRECIPITATE OR BLOOD PLASMA-OPTIONALLY FOLLOWED BY ALUMINUM HYDROXIDE TREATMENT, AFTER DISSOLUTION OF THE CRYOPRECIPITATE AT LEAST ONE SEPARATION STEP USING MEMBRANCE CHROMATOGRAPHY IS PERFORWED.THE FRACTIONS ARE SUBJECTED TO VIRUS INACTIVATION AND PREFERABLY TO AN ADDITIONAL PASTEURIZATION STEP.
MYPI94002921A 1993-11-04 1994-11-03 A process for the preparation of a virus inactivated fraction containing factor viii by means of chromatographic methods MY113294A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4337573A DE4337573C1 (en) 1993-11-04 1993-11-04 Process for the preparation of a virus-inactivated factor VIII-containing fraction by means of chromatographic methods

Publications (1)

Publication Number Publication Date
MY113294A true MY113294A (en) 2002-01-31

Family

ID=6501733

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI94002921A MY113294A (en) 1993-11-04 1994-11-03 A process for the preparation of a virus inactivated fraction containing factor viii by means of chromatographic methods

Country Status (21)

Country Link
EP (1) EP0726907B1 (en)
JP (1) JP3739788B2 (en)
KR (1) KR960705841A (en)
CN (1) CN1109045C (en)
AT (1) ATE228533T1 (en)
AU (1) AU687451B2 (en)
CA (1) CA2175670C (en)
CZ (1) CZ290186B6 (en)
DE (2) DE4337573C1 (en)
ES (1) ES2182846T3 (en)
FI (1) FI116569B (en)
HU (1) HU222087B1 (en)
IL (1) IL111263A (en)
MY (1) MY113294A (en)
NO (1) NO317112B1 (en)
PL (1) PL181725B1 (en)
RU (1) RU2148411C1 (en)
SK (1) SK284215B6 (en)
UA (1) UA43855C2 (en)
WO (1) WO1995012609A1 (en)
ZA (1) ZA948667B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885394B1 (en) * 1996-03-08 2000-08-16 Octapharma AG Process for testing suitability of protein fractions containing factor viii
DE19618851C1 (en) * 1996-05-10 1997-07-24 Octapharma Ag Testing factor VIII containing preparations
ES2137878B1 (en) * 1997-12-01 2000-10-01 Grifols Grupo Sa PROCEDURE FOR OBTAINING AN ATTENUATED HUMAN PLASMA OF VIRUSES FOR THERAPEUTIC USE.
RU2253475C1 (en) * 2004-02-02 2005-06-10 Общество с ограниченной ответственностью "Гемоцентр" Method of preparing factor viii preparation
RU2324495C1 (en) * 2006-08-31 2008-05-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Method of making preparation of human blood coagulaton factor viii
PL2300497T3 (en) * 2008-06-24 2013-02-28 Octapharma Ag A process of purifying coagulation factor viii
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5043428A (en) * 1984-08-31 1991-08-27 Behringwerke Aktiengesellschaft Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
DE3432083A1 (en) * 1984-08-31 1986-03-06 Behringwerke Ag, 3550 Marburg PASTEURIZED, ISOAGGLUTININ-FREE FACTOR VIII PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
JPS62191042A (en) * 1986-02-17 1987-08-21 Kanegafuchi Chem Ind Co Ltd Blood coagulation factor viii adsorbent and method for purifying blood coagulation factor viii using same
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
US4795806A (en) * 1987-07-16 1989-01-03 Miles Laboratories, Inc. Phospholipid affinity purification of Factor VIII:C
CA2001720C (en) * 1988-10-31 2001-10-02 Randal A. Goffe Membrane affinity apparatus and purification methods related thereto
EP0367840B1 (en) * 1988-11-05 1993-02-03 Octapharma AG Process for producing by chromatography a non-infectious antihemophilic factor with high purity
CH678155A5 (en) * 1989-08-09 1991-08-15 Fischer Ag Georg
AT399818B (en) * 1992-04-24 1995-07-25 Immuno Ag METHOD FOR PRODUCING A HIGH PURIFIED VIRUS-SAFE FACTOR VIII PREPARATION

Also Published As

Publication number Publication date
SK284215B6 (en) 2004-11-03
ATE228533T1 (en) 2002-12-15
JP3739788B2 (en) 2006-01-25
HU9601192D0 (en) 1996-06-28
PL314185A1 (en) 1996-09-02
EP0726907B1 (en) 2002-11-27
CA2175670C (en) 2005-08-02
CZ290186B6 (en) 2002-06-12
CN1134157A (en) 1996-10-23
SK56696A3 (en) 1996-10-02
CA2175670A1 (en) 1995-05-11
FI116569B (en) 2005-12-30
ES2182846T3 (en) 2003-03-16
DE4337573C1 (en) 1995-05-18
NO961816D0 (en) 1996-05-03
NO317112B1 (en) 2004-08-16
UA43855C2 (en) 2002-01-15
AU7810994A (en) 1995-05-23
IL111263A0 (en) 1994-12-29
EP0726907A1 (en) 1996-08-21
FI961900A0 (en) 1996-05-03
DE59410213D1 (en) 2003-01-09
FI961900L (en) 1996-05-03
ZA948667B (en) 1995-07-07
HU222087B1 (en) 2003-04-28
AU687451B2 (en) 1998-02-26
WO1995012609A1 (en) 1995-05-11
HUT76530A (en) 1997-09-29
CN1109045C (en) 2003-05-21
IL111263A (en) 2000-07-16
CZ118796A3 (en) 1996-12-11
KR960705841A (en) 1996-11-08
NO961816L (en) 1996-05-03
JPH09504532A (en) 1997-05-06
PL181725B1 (en) 2001-09-28
RU2148411C1 (en) 2000-05-10

Similar Documents

Publication Publication Date Title
GR3003819T3 (en)
DE359593T1 (en) CHROMATOGRAPHIC SEPARATION OF PLASMA PROTEINS.
NO920834D0 (en) PROCEDURE FOR INACTIVATION OF VIRUS IN BLOOD AND BLOOD PRODUCTS
AU580402B2 (en) Method of inactivating viruses involving adsorption on solid phase
AU8172094A (en) Synthetic HTLV-III peptides, compositions and uses thereof
EP0431129A4 (en) Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
ZA944488B (en) System for viral inactivation of blood
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
ES2173927T3 (en) PROCEDURE FOR THE PREPARATION OF AN INTER-ALFA-TRIPSIN CONCENTRATE INHIBITOR FOR THERAPEUTIC USE, AND CONCENTRATE OBTAINED.
AU4101589A (en) Pharmaceutical preparations which can be applied transdermally, containing sterolins and/or spiroketalins
ZA948667B (en) A process for the preparation of a virus inactivated fraction containing factor VIII by means of chromatographic methods
AU561222B2 (en) Process for the pasteurization of human plasma
AU8200791A (en) Ehv-4 glycoprotein vaccine
GR3005036T3 (en)
DE69309790D1 (en) Cyclopentane perhydrophenanthrene-17-beta (3-furyl) -3 derivatives and pharmaceutical preparations thereof, for the treatment of cardiovascular diseases
ATE329602T1 (en) METHOD FOR PRODUCING PURIFIED TRANSFERRIN
ES2117197T3 (en) PROCEDURE FOR THE EXTRACTION AND PURIFICATION OF ALFA1-ANTI-TRYPSINE (ALFA1-PI) FROM THE COHN IV-1 FRACTION.
DK0536564T3 (en) Process for the preparation of streptolysin O, intact streptolysin O prepared by this method and its use
AU6297590A (en) Method for the treatment of carcasses or parts of these
AU4660889A (en) Method of treatment of human immunodeficiency virus
GR1001635B (en) Process for preparing 3-Ä2-(dimethylamino)-ethylÜ-nmethyl-1h-indole-5-methanesulphonamide.
RO102458B1 (en) Process for isolating human, high pureness igm, m immumoglobulin